Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	150	103	67	123	128	163
Market Cap Growth	18.52%	52.89%	-45.33%	-3.92%	-21.42%	15.30%
Enterprise Value	209	149	88	112	101	115
PE Ratio	-	-2.29	-1.73	-4.00	-5.42	-8.06
PB Ratio	-2.03	-1.66	-1.98	137.56	5.69	3.71
P/FCF Ratio	-4.32	-3.11	-2.16	-5.05	-6.21	-15.00
P/OCF Ratio	-4.32	-3.11	-2.16	-5.05	-6.21	-15.00
EV/EBITDA Ratio	-5.01	-3.55	-2.34	-3.74	-4.31	-8.75
EV/EBIT Ratio	-5.01	-3.55	-2.34	-3.74	-4.31	-8.72
EV/FCF Ratio	-6.03	-4.51	-2.85	-4.62	-4.89	-10.62
Debt / Equity Ratio	-1.13	-1.16	-1.17	32.53	-	-
Debt / EBITDA Ratio	-2.00	-1.71	-1.06	-0.97	-	-
Debt / FCF Ratio	-2.41	-2.18	-1.28	-1.19	-	-
Quick Ratio	1.86	1.64	1.43	4.39	5.03	16.84
Current Ratio	2.02	1.77	1.58	4.63	5.46	17.10
Interest Coverage	-12.19	-15.00	-36.54	-61.43	-268.71	-151.80
Return on Equity (ROE)	74.60%	84.60%	187.70%	-304.50%	-73.40%	-55.00%
Return on Assets (ROA)	-185.90%	-197.70%	-157.50%	-90.20%	-63.30%	-50.40%
Return on Capital (ROIC)	-387.18%	-389.40%	-648.82%	-100.79%	-104.33%	-30.63%
Earnings Yield	-29.77%	-43.64%	-57.89%	-24.99%	-18.46%	-12.40%
FCF Yield	-22.79%	-32.11%	-46.25%	-19.79%	-16.11%	-6.67%
Buyback Yield / Dilution	-4.20%	-1.29%	-1.48%	-2.63%	-9.17%	-32.54%
Total Shareholder Return	-4.20%	-1.29%	-1.48%	-2.63%	-9.17%	-32.54%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).